Biotechnology Startup Secures $209,565 SBIR Phase I Award for Breakthrough Vaccine Stabilization Technology
$209,565 secured | 6-month research timeline established
Proposal writing, project management, and strategic advisory services
Overview
BW&CO partnered with an early-stage biotechnology company developing revolutionary vaccine preservation technology to secure a competitive Department of Defense SBIR Phase I award. Through comprehensive proposal development and strategic positioning, we helped the client articulate their breakthrough approach to thermal stabilization of biologicals, positioning them to address critical supply chain vulnerabilities in medical countermeasures while advancing their proprietary dehydration technology toward commercialization.
The Challenge
The client possessed groundbreaking Rapid Room-Temperature Aerosol Dehydration (RTAD) technology with the potential to eliminate cold chain requirements for vaccines and biologicals—a persistent $2+ billion annual problem affecting global healthcare delivery. However, the company faced several obstacles in pursuing federal funding. Their highly technical innovation required translation into language that clearly demonstrated military and public health applications. The competitive SBIR landscape demanded precise alignment between their capabilities and specific DoD priorities, particularly around medical countermeasures and supply chain resilience. Additionally, the client needed to establish a credible 6-month research plan that would demonstrate feasibility while positioning them for Phase II funding opportunities.
Our Approach
BW&CO provided end-to-end support to maximize the client's competitive positioning:
Technical narrative development: Translated complex dehydration science into compelling problem-solution messaging that highlighted military logistics applications and public health emergency preparedness
Market research and validation: Conducted comprehensive analysis of cold chain failures, vaccine waste statistics, and military deployment challenges to strengthen the business case
Regulatory and compliance guidance: Ensured proposal alignment with DoD priorities under topic CBD254-001 while addressing biosafety and manufacturing scalability requirements
Project management framework: Developed detailed milestone-based research plan with clear deliverables, risk mitigation strategies, and success metrics
Proposal optimization: Managed multiple review cycles, stakeholder feedback integration, and final submission logistics to meet strict federal deadlines
Results
The client successfully secured the full $209,565 Phase I award from the DoD Chemical and Biological Defense program, validating their technology's potential to address critical national security and public health needs. The funded research plan positions them to demonstrate RTAD technology efficacy using modified vaccinia Ankara vaccine as a model system, directly addressing supply chain vulnerabilities exposed during the 2022 mpox outbreak. Beyond the immediate funding, the SBIR award establishes credibility with investors, potential pharmaceutical partners, and regulatory agencies while providing a clear pathway toward Phase II applications worth up to $1.7 million. The client is now positioned to advance their technology from laboratory concept toward clinical validation and eventual commercialization, with potential applications spanning vaccines, monoclonal antibodies, and other temperature-sensitive biologics representing 75% of top-selling pharmaceuticals.